摘要号：LBA5500

BrUOG 354研究的最终结果：纳武利尤单抗±伊匹木单抗治疗卵巢癌和其他肾外透明细胞癌患者的随机Ⅱ期试验

Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.

讲者：Don S. Dizon

罗德岛普罗维登斯市RI Fospin癌症研究所

摘要号：LBA5501

AGO-OVAR 2.29/ENGOT-ov34研究的最终OS和PFS结果：阿替利珠单抗+贝伐珠单抗+非铂类化疗 vs. 安慰剂+贝伐珠单抗+非铂类化疗治疗复发性卵巢癌

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.

讲者：Frederik Marmé

德国海德堡大学曼海姆医学院

摘要号：5502

Ⅱ期KEYVIBE-005研究的B1队列结果：vibostolimab +帕博利珠单抗（vibo/pembro）治疗既往经治的晚期错配修复缺陷（dMMR）子宫内膜癌

Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.

讲者：Carlos Rojas

布拉德福德山临床研究中心

摘要号：5503

妇科肿瘤靶向治疗的3期临床试验的趋势：过去12年的研究监督和制药参与。

Trends in phase 3 gynecological clinical trials of targeted therapies: Study oversight and pharmaceutical involvement in the past 12 years.

讲者：Qiao Ruan

加利福尼亚太平洋医疗中心

摘要号：5504

NRG oncology/RTOG 0724/GOG-0724研究结果：接受根治性子宫切除术的高危早期宫颈癌患者同步放化疗（CRT）后进行辅助化疗

Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy: Results of NRG oncology/RTOG 0724/GOG-0724.

讲者：Anuja Jhingran

德州大学安德森癌症中心

摘要号：LBA5505

接受初次肿瘤细胞减灭术或新辅助化疗联合间歇性肿瘤细胞减灭术的晚期上皮性卵巢癌患者省略淋巴结清扫术：CARACO III 期随机试验。

Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: The CARACO phase III randomized trial.

讲者：Jean-Marc Classe

南特大学

摘要号：5506

NEO研究：奥拉帕利新辅助治疗铂敏感复发高级别浆液性卵巢癌的Ⅱ期随机多中心研究

Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.

讲者：Stephanie Lheureux

玛嘉烈公主癌症中心

摘要号：5508

绝经前临床 I 期子宫内膜癌患者激素治疗的长期生存结果。

Long-term survival outcomes for hormonal therapy in premenopausal patients with clinical stage I endometrial cancer.

讲者：Yukio Suzuki

哥伦比亚大学医学院

摘要号：5509

TORC1/2抑制剂onatasertib联合特瑞普利单抗治疗晚期实体瘤患者的I/II期研究：宫颈癌队列

A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort.

讲者：Xiaoyu Li

四川华西医院

摘要号：5510

ATR抑制剂联合PARP抑制剂（CAPRI）：一项ceralasertib联合奥拉帕利治疗铂敏感复发性上皮性卵巢癌的Ⅱ期研究（队列A）

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A).

讲者：Fiona Simpkins

宾夕法尼亚大学Abramson癌症中心

摘要号：5511

一项氟维司群+阿贝西利治疗激素受体阳性晚期或复发性子宫内膜癌的Ⅱ期研究

A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer.

讲者：Angela Green

纪念斯隆凯特琳癌症中心MSKCC

摘要号：5512

信迪利单抗联合紫杉醇和顺铂新辅助治疗局部晚期宫颈癌的有效性和安全性：一项II期研究

Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial.

讲者：刘继红

中山大学肿瘤防治中心

摘要号：5513

一项开放、单臂、Ⅱ期、多中心研究：度伐利尤单抗联合BVAC-C治疗一线铂类化疗失败的HPV 16或18阳性宫颈癌患者（DURBAC）

An open label, single arm phase II, multicenter trial of durvalumab and BVAC-C, in patients with HPV 16- or 18-positive cervical cancer and failure of first-line platinum-based chemotherapy (DURBAC).

讲者：Chel Hun Choi

三星医学中心

摘要号：5514

尼妥珠单抗联合同步放化疗治疗局部晚期宫颈鳞状细胞癌：随机、III期CC3研究

Nimotuzumab plus concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma: The randomized, phase 3 CC3 study.

讲者：王俊杰

北京大学第三医院

摘要号：LBA5515

AXLerate-OC/GOG-3059/ENGOT OV-66：batiraexept（AVB-S6-500）联合紫杉醇治疗铂耐药复发性卵巢癌的Ⅲ期、随机、双盲、安慰剂/紫杉醇对照研究结果

AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer.

讲者：Katherine Cynthia Fuh

加利福尼亚大学旧金山分校

摘要号：LBA5516

suvemcitug联合化疗治疗铂类耐药卵巢癌的随机、双盲、安慰剂对照III期研究(SCORES)

A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES).

讲者：袁光文

中国医学科学院肿瘤医院

摘要号：5517

口服环磷酰胺加贝伐珠单抗治疗复发性卵巢癌、输卵管癌和原发性腹膜癌。

Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer.

讲者：Mostafa Eyada

德克萨斯大学医学分校

摘要号：5518

一项随机试验中复发性铂耐药卵巢癌患者癌症干细胞功能测定与客观缓解率的关系。

Relationship of cancer stem cell functional assay and objective response rate of patients with recurrent platinum-resistant ovarian cancer in a randomized trial.

讲者：Thomas J. Herzog

辛辛那提大学

摘要号：5519

腹膜内化疗的优化：随机 II 期 GERCOR CHIMOVIP 研究。

Optimization of intra-peritoneal chemotherapy: Randomized phase II GERCOR CHIMOVIP study.

讲者：Romain Cohen

索邦大学

摘要号：5520

对铂敏感的复发性卵巢癌患者进行二次减瘤术后序贯化疗与单纯化疗的比较：一项多中心、开放标签、随机、III期试验(SOC-1)的最终总生存期分析

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis of a multicenter, open-label, randomized, phase 3 trial.

讲者：臧荣余

复旦大学附属中山医院